Prime Medicine, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Prime Medicine, Inc. (PRME) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $5.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.87M, a 22.06% increase year-over-year.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.84M, a 17.82% increase year-over-year.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.60M, a 17.89% increase year-over-year.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.33M, a 4.66% increase year-over-year.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $9.70M, a 21.51% decline from fiscal 2024.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $12.36M, a 3.39% decline from fiscal 2023.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $12.79M, a 30.62% increase from fiscal 2022.
- Prime Medicine, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $9.79M, a 128.05% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.71M 10-Q · filed 2026-08-06 | $8.31M derived: sum of 3 quarters · filed 2026-08-06 | $10.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.84M 10-Q · filed 2026-05-07 | $5.45M derived: sum of 2 quarters · filed 2026-05-07 | $7.78M derived: sum of 3 quarters · filed 2026-05-07 | $10.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.94M derived: sum of 2 quarters · filed 2026-03-03 | $7.29M derived: sum of 3 quarters · filed 2026-08-06 | $9.70M 10-K · filed 2026-03-03 |
| 2025-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.68M derived: sum of 2 quarters · filed 2026-08-06 | $7.09M 10-Q · filed 2025-11-07 | $9.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.76M 10-Q · filed 2026-08-06 | $6.97M derived: sum of 3 quarters · filed 2026-08-06 | $9.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.41M 10-Q · filed 2026-05-07 | $4.62M derived: sum of 2 quarters · filed 2026-05-07 | $6.85M derived: sum of 3 quarters · filed 2026-05-07 | $11.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.44M derived: sum of 2 quarters · filed 2026-03-03 | $9.01M derived: sum of 3 quarters · filed 2026-03-03 | $12.36M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $6.80M derived: sum of 2 quarters · filed 2025-11-07 | $10.15M 10-Q · filed 2025-11-07 | $13.49M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.92M 10-Q · filed 2025-08-07 | $11.27M derived: sum of 3 quarters · filed 2025-08-07 | $14.40M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.35M 10-Q · filed 2025-05-08 | $6.70M derived: sum of 2 quarters · filed 2025-05-08 | $9.83M derived: sum of 3 quarters · filed 2025-05-08 | $13.30M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $6.48M derived: sum of 2 quarters · filed 2025-02-28 | $9.96M derived: sum of 3 quarters · filed 2025-02-28 | $12.79M 10-K · filed 2025-02-28 |
| 2023-09-30 | $3.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.61M derived: sum of 2 quarters · filed 2024-11-12 | $9.44M 10-Q · filed 2024-11-12 | $12.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.30M 10-Q · filed 2024-08-08 | $9.10M derived: sum of 3 quarters · filed 2024-08-08 | $11.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.83M 10-Q · filed 2024-05-10 | $5.63M derived: sum of 2 quarters · filed 2024-05-10 | $8.40M derived: sum of 3 quarters · filed 2024-05-10 | $10.85M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $5.57M derived: sum of 2 quarters · filed 2024-03-01 | $8.02M derived: sum of 3 quarters · filed 2024-03-01 | $9.79M 10-K · filed 2024-03-01 |
| 2022-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $5.22M derived: sum of 2 quarters · filed 2023-11-03 | $6.99M 10-Q · filed 2023-11-03 | $8.38M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $4.22M 10-Q · filed 2023-08-07 | $5.61M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $1.77M 10-Q · filed 2023-05-11 | $3.16M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.29M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $2.91M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |